• linkedin
  • Increase Font
  • Sharebar

    Atopic dermatitis: Biologics to watch in 2018

    The future of biologic treatment for atopic dermatitis may be quite diverse. While dupilumab represents the approved first biologic therapy for atopic dermatitis, 2018 may bring news on a variety of subcutaneously or intravenously administered biologic drugs under investigation that target specific molecules including IL13, IL17, and more.

    The developments are part of a “growing movement towards the use of targeted therapies in treating atopic dermatitis, parallel to that which occurred in psoriasis,” write Lindsay C. Strowd, M.D., and Nupur Patel, MS, in a review published in Advances in Experimental Medicine and Biology.

    Ongoing clinical trials may shed more light on the role of dupilumab, a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 by binding the IL-4Rα subunit that the IL-4 and IL-13 receptor complexes share, wrote the authors, both from Wake Forest University School of Medicine in North Carolina.

    Phase 3 trial data already reported from the identically designed SOLO1 and SOLO2 trials should that dupilumab improved the signs and symptoms of atopic dermatitis versus placebo in adults after 16 weeks of treatment. More recently, the LIBERTY AD CHRONOS study showed that dupilumab, added to standard topical corticosteroid treatment for 1 year had acceptable safety and improved atopic dermatitis in adults.

    Other studies of dupilumab are ongoing, including a Phase 3 study evaluating the efficacy and safety of dupilumab vs placebo in patients between 12 and 18 years of age with moderate-to-severe atopic dermatitis.

    But dupilumab may be just the beginning in terms of effective biologic therapies for atopic dermatitis in 2018 and beyond.

    NEXT: Targeting IL-13

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available
    Derm Pulse
    Article image

    ©TED

    Brought to you by:

    Ortho Derm

    Latest Tweets Follow